Clinical Trial Update: Low Dose Sirolimus or CsA-Based Maintenance Immunosuppression After Induction With Campath-1 in Kidney Transplantation [Phase 2]

View source ↗

Summary

This completed Phase 2 trial evaluated maintenance immunosuppression with low-dose sirolimus or cyclosporine after alemtuzumab (Campath-1) induction in kidney t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation

Drugs mentioned

• CAMPATH (ALEMTUZUMAB)
• NEORAL (CYCLOSPORINE)
• Rapamune (sirolimus)

Snippet

Sponsor: Mario Negri Institute for Pharmacological Research | Conditions: Kidney Transplant | Phase 2 | Status: COMPLETED